Compass Therapeutics (CMPX) Operating Expenses (2023 - 2025)
Historic Operating Expenses for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $15.8 million.
- Compass Therapeutics' Operating Expenses rose 2923.44% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.4 million, marking a year-over-year increase of 2686.82%. This contributed to the annual value of $57.5 million for FY2024, which is 1412.15% up from last year.
- Latest data reveals that Compass Therapeutics reported Operating Expenses of $15.8 million as of Q3 2025, which was up 2923.44% from $21.1 million recorded in Q2 2025.
- In the past 5 years, Compass Therapeutics' Operating Expenses registered a high of $21.1 million during Q2 2025, and its lowest value of $9.7 million during Q1 2023.
- Moreover, its 3-year median value for Operating Expenses was $15.4 million (2023), whereas its average is $14.8 million.
- In the last 5 years, Compass Therapeutics' Operating Expenses soared by 262.45% in 2024 and then surged by 4068.91% in 2025.
- Quarter analysis of 3 years shows Compass Therapeutics' Operating Expenses stood at $15.4 million in 2023, then rose by 7.67% to $16.6 million in 2024, then decreased by 4.57% to $15.8 million in 2025.
- Its last three reported values are $15.8 million in Q3 2025, $21.1 million for Q2 2025, and $18.0 million during Q1 2025.